Abstract
Introduction/Background: Multimodal neoadjuvant therapy has resulted in increased rates of histologic response in pancreatic tumors and adjacent lymph nodes. The biologic significance of the collective response in the primary tumor and lymph nodes is not understood.Methods: Patients with localized PC who received neoadjuvant therapy and surgery with histologic assessment of the primary tumor and local-regional lymph nodes were included. Histopathologic response was classified using the modified Ryan score as follows: no viable cancer cells (CR), rare groups of cancer cells (nCR), residual cancer with evident tumor regression (PR), and extensive residual cancer with no evident tumor regression (NR). Nodal status was defined by number of lymph nodes (LN) with tumor metastases: N0 (0 LN), N1 (1–3), N2 (≥4).Results: Of 341 patients with localized PC who received neoadjuvant therapy and surgery, 107 (31%) received chemoradiation alone, 44 (13%) received chemotherapy alone, and 190 (56%) received chemotherapy and chemoradiation. Histopathologic response consisted of 15 (4%) CRs, 59 (17%) nCRs, 188 (55%) PRs, and 79 (23%) NRs. Patients who received chemotherapy alone had the worst responses (n = 21 for NR, 48%) as compared to patients who received chemoradiation alone (n = 25 for NR, 24%) or patients who received both therapies (n = 33 for NR, 17%) (Table 1; p = 0.001). Median overall survival for all 341 patients was 39 months; OS by histopathologic subtype was not reached (CR), 49 months (nCR), 38 months (PR), and 34 months (NR), respectively (p = 0.004). Of the 341 patients, 208 (61%) had N0 disease, 97 (28%) had N1 disease, and 36 (11%) had N2 disease. In an adjusted hazards model, modified Ryan score of PR or NR (HR: 1.71; 95% CI: 1.15–2.54; p = 0.008) and N1 (HR: 1.42; 95% CI: 1.1.02–2.01; p = 0.04), or N2 disease (HR: 2.54, 95% CI: 1.64–3.93; p < 0.001) were associated with increased risk of death.Conclusions: Neoadjuvant chemotherapy alone is associated with lower rates of pathologic response. Patients with CR or nCR have a significantly improved OS as compared to patients with PR or NR. Nodal status is the most important pathologic prognostic factor. Neoadjuvant chemoradiation may be an important driver of pathologic response.
Highlights
In the past decade, there has been significant progress in the treatment sequencing of patients with localized pancreatic cancer (PC) [1]
For patients with borderline resectable (BLR) PC, neoadjuvant therapy consisted of a minimum of 2 months of chemotherapy followed by chemoradiation (50.4 Gy over 28 fractions)
From 2009 to 2018, 517 patients with resectable (n = 216, 42%) or BLR (n = 301, 58%) PC were treated with neoadjuvant therapy
Summary
There has been significant progress in the treatment sequencing of patients with localized pancreatic cancer (PC) [1]. Neoadjuvant therapy has become the standard treatment for borderline resectable (BLR) PC and has been adopted at multiple centers for the management of resectable disease as well [2, 3]. Neoadjuvant therapy has been increasingly accepted as the preferred treatment paradigm for patients with localized PC, there remains a lack of consensus regarding the optimal regimen and treatment duration. As systemic disease control improves, locoregional recurrence in patients with PC may become even more problematic; at present, up to 50% of patients have a positive resection (R1) margin following upfront surgical resection and isolated local recurrence occurs in a minimum of 24–50% of patients who undergo potentially curative surgery [5,6,7]. The results of the ongoing Alliance (A021501) trial for patients with BLR PC in which patients are randomized to receive neoadjuvant chemotherapy with or without stereotactic body radiation are eagerly anticipated (NCT02839343)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
